Tag: Parkinson’s

Models including disease exposure indexes predict gray matter atrophy accumulation

Benefits persist four weeks after treatment

Change in digital measures over 12 months generally larger than corresponding change in individual items of the Movement Disorder Society scale

Infusion increases on time without troublesome dyskinesia and reduces daily off time

Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson disease

Highest versus lowest decile of application of simazine, lindane, atrazine linked to increased relative risks for Parkinson disease

PDQ-8 and ADL worsened in standard-of-care medication group, remained stable in stimulation group

All nine LBD+ participants had low 18F-dopamine-derived radioactivity before or at the time of diagnosis of central LBD

Improvements seen in motor and nonmotor symptoms, reductions in disability and complications

Findings persist across demographic groups and independent of depression and other prominent risk factors, including genetic risk